Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLC

Emerald Advisers LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 20.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 369,600 shares of the company’s stock after acquiring an additional 63,834 shares during the quarter. Emerald Advisers LLC owned about 0.74% of Mirum Pharmaceuticals worth $27,095,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MIRM. Jump Financial LLC grew its position in shares of Mirum Pharmaceuticals by 839.7% during the second quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock worth $7,567,000 after acquiring an additional 132,866 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $1,728,000. Eventide Asset Management LLC raised its position in Mirum Pharmaceuticals by 4.4% in the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after purchasing an additional 110,485 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new stake in Mirum Pharmaceuticals during the 2nd quarter worth $11,071,000. Finally, Boone Capital Management LLC grew its position in Mirum Pharmaceuticals by 6.3% during the 2nd quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock worth $32,643,000 after purchasing an additional 38,130 shares during the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of a number of research reports. JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. HC Wainwright reaffirmed a “buy” rating and set a $102.00 price objective (up from $81.00) on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 13th. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.58.

Mirum Pharmaceuticals Trading Up 1.5%

Shares of MIRM stock opened at $93.27 on Thursday. The business’s fifty day moving average price is $76.34 and its 200 day moving average price is $70.16. The firm has a market capitalization of $4.79 billion, a PE ratio of -108.45 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.88 and a 1-year high of $93.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same quarter last year, the company earned ($0.30) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 47.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 6,911 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97. Following the transaction, the insider directly owned 11,305 shares in the company, valued at approximately $1,020,502.35. This represents a 37.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.